Technical Analysis for LPCN - Lipocine Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Inside Day | Range Contraction | -1.05% | |
| Wide Bands | Range Expansion | -1.05% | |
| Oversold Stochastic | Weakness | -1.05% | |
| MACD Bearish Centerline Cross | Bearish | -0.21% | |
| Stochastic Reached Oversold | Weakness | -0.21% | |
| Lower Bollinger Band Touch | Weakness | -0.21% | |
| Oversold Stochastic | Weakness | -0.21% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 16 hours ago |
| Down 2 % | about 16 hours ago |
| Down 1% | about 16 hours ago |
| Possible NR7 | about 17 hours ago |
| Possible Inside Day | about 17 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/06/2024
Lipocine Inc. Description
Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Alcohol Pharmaceutical Products Gastrointestinal Clinical Research Clinical Trial Metabolism Bypass Ketones Testosterone Androstanes Preterm Birth
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.79 |
| 52 Week Low | 2.38 |
| Average Volume | 32,561 |
| 200-Day Moving Average | 5.28 |
| 50-Day Moving Average | 5.08 |
| 20-Day Moving Average | 5.39 |
| 10-Day Moving Average | 5.03 |
| Average True Range | 0.46 |
| RSI (14) | 41.18 |
| ADX | 27.62 |
| +DI | 11.30 |
| -DI | 17.86 |
| Chandelier Exit (Long, 3 ATRs) | 4.79 |
| Chandelier Exit (Short, 3 ATRs) | 6.01 |
| Upper Bollinger Bands | 6.30 |
| Lower Bollinger Band | 4.49 |
| Percent B (%b) | 0.12 |
| BandWidth | 33.59 |
| MACD Line | -0.10 |
| MACD Signal Line | 0.03 |
| MACD Histogram | -0.13 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.22 | ||||
| Resistance 3 (R3) | 5.26 | 5.12 | 5.14 | ||
| Resistance 2 (R2) | 5.12 | 4.99 | 5.10 | 5.11 | |
| Resistance 1 (R1) | 4.91 | 4.91 | 4.85 | 4.88 | 5.08 |
| Pivot Point | 4.78 | 4.78 | 4.74 | 4.76 | 4.78 |
| Support 1 (S1) | 4.57 | 4.65 | 4.50 | 4.54 | 4.34 |
| Support 2 (S2) | 4.43 | 4.56 | 4.42 | 4.31 | |
| Support 3 (S3) | 4.23 | 4.43 | 4.28 | ||
| Support 4 (S4) | 4.20 |
